deltatrials
Completed PHASE4 INTERVENTIONAL 2-arm NCT00330551

Oral Versus Injectable Risperidone for Treating First-Episode Schizophrenia

Effects of Risperdal Consta Versus Oral Antipsychotic Medication on Clinical and Functional Outcome and Neurocognition in First-episode Schizophrenia

Sponsor: Janssen Scientific Affairs, LLC

Conditions Schizophrenia
Interventions Oral Risperidone Risperidone in Long-Acting Injectable Form (Consta)
Updated 11 times since 2017 Last updated: Feb 4, 2023 Started: Mar 31, 2006 Primary completion: Nov 30, 2012 Completion: Nov 30, 2012
This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

Listed as NCT00330551, this PHASE4 trial focuses on Schizophrenia and remains completed. Sponsored by Janssen Scientific Affairs, LLC, it has been updated 11 times since 2006, reflecting substantial change activity. Mental health research at this phase helps define safety and dosing parameters for future study.

Status Flow

~Jan 2017 – ~Feb 2017 · 31 days · monthly snapshotCompleted~Feb 2017 – ~Jun 2018 · 16 months · monthly snapshotCompleted~Jun 2018 – ~Apr 2020 · 22 months · monthly snapshotCompleted~Apr 2020 – ~Jan 2021 · 9 months · monthly snapshotCompleted~Jan 2021 – ~Dec 2021 · 11 months · monthly snapshotCompleted~Dec 2021 – ~Dec 2022 · 12 months · monthly snapshotCompleted~Dec 2022 – ~Jan 2023 · 31 days · monthly snapshotCompleted~Jan 2023 – ~Apr 2023 · 3 months · monthly snapshotCompleted~Apr 2023 – ~Jul 2024 · 15 months · monthly snapshotCompleted~Jul 2024 – ~Sep 2024 · 2 months · monthly snapshotCompleted~Sep 2024 – present · 20 months · monthly snapshotCompleted

Change History

11 versions recorded

  1. Sep 2024 — Present [monthly]

    Completed PHASE4

  2. Jul 2024 — Sep 2024 [monthly]

    Completed PHASE4

  3. Apr 2023 — Jul 2024 [monthly]

    Completed PHASE4

  4. Jan 2023 — Apr 2023 [monthly]

    Completed PHASE4

  5. Dec 2022 — Jan 2023 [monthly]

    Completed PHASE4

▶ Show 6 earlier versions

  1. Dec 2021 — Dec 2022 [monthly]

    Completed PHASE4

  2. Jan 2021 — Dec 2021 [monthly]

    Completed PHASE4

  3. Apr 2020 — Jan 2021 [monthly]

    Completed PHASE4

  4. Jun 2018 — Apr 2020 [monthly]

    Completed PHASE4

  5. Feb 2017 — Jun 2018 [monthly]

    Completed PHASE4

  6. Jan 2017 — Feb 2017 [monthly]

    Completed PHASE4

    First recorded

Mar 2006

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:
  • Janssen Scientific Affairs, LLC
  • National Institute of Mental Health (NIMH)
  • University of California, Los Angeles
Data source: University of California, Los Angeles

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations